1. Introduction {#sec1}
===============

Snoring is commonly described as a coarse and vibratory sound during sleep resulting from partial obstruction of inspiration in the oropharynx \[[@B1]\]. The prevalence of snoring varies from 2% to 85% \[[@B1]--[@B3]\]. Simple snoring may represent the beginning of a sleep-disordered breathing (SDB) continuum, which ranges from partial airway collapse and mildly increased upper airway resistance to complete airway collapse and severe obstructive sleep apnea (OSA) lasting for 60 s or more \[[@B2], [@B4]\]. There is accumulating evidence that snoring is associated with several health problems, including sleepiness, cardiovascular diseases, metabolic syndrome (MetS), and all-cause mortality \[[@B5]--[@B7]\].

MetS, a combination of excess abdominal obesity, dyslipidemia, hypertension, hyperglycemia, and insulin resistance (IR) \[[@B8]\], is related to increased risk of cardiovascular events and mortality \[[@B9]\]. Previous studies have demonstrated a relationship between snoring and MetS, but patients with OSA were not excluded from the study populations \[[@B10]--[@B12]\]. Such association between snoring and MetS may be mediated by OSA, as heavy snoring is always accompanied with sleep apnea \[[@B3]\], and both snoring and sleep apnea are related to mechanical obstruction of the upper airway \[[@B13]\]. However, most common snorers do not have OSA \[[@B4]\]. Therefore, further research is required to determine whether simple snoring itself, as a more common disease, is independently related to increased odds for MetS and its components.

To exclude the effects of more severe sleep apnea, we conducted a cross-sectional study among non-OSA participants to examine whether simple snoring itself is associated with increased odds for MetS and metabolic disorders, such as obesity, hypertension, dyslipidemia, and IR.

2. Methods {#sec2}
==========

A total of 5635 participants were initially included in the study. Among them, 300 were healthy volunteers specially recruited without snoring allegedly; the other participants were patients referring to the sleep center of Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital for suspected SDB from 2007 to 2016. They were mainly from cities in southeastern China and all completed surveys regarding smoking habits, alcohol consumption, and medical history. 4769 participants were excluded for the following reasons: return visit; age \< 18 years; taking lipid-reducing medications prior to the study, which could affect the serum lipid profiles\' levels; various systemic diseases (i.e., malignancy, chronic kidney disease, and unstable cardiopulmonary diseases, such as congestive heart failure or intrinsic pulmonary disease); diagnosis of SDB; and missing data (lacking information of smoking, drinking, lipid-lowering medication taking, etc.). Finally, a total of 866 participants including 187 nonsnorers and 679 simple snorers were enrolled in the analysis ([Figure 1](#fig1){ref-type="fig"}). Written informed consent was obtained from each participant according to the guidelines outlined by the National Ethics Regulation Committee. This study was approved by the Internal Review Board of the Institutional Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital and was conducted in accordance with the tenets of the Declaration of Helsinki.

2.1. Anthropometric and Metabolic Measurements {#sec2.1}
----------------------------------------------

All measurements were performed using the standard methods mentioned in our previous research \[[@B14]\], with the participants dressed in lightweight clothing and with bare feet. Body mass index (BMI) was calculated as body mass in kilograms divided by the square of the patient\'s height in meters. Neck circumference (NC) was measured at the level of laryngeal prominence, waist circumference (WC) in the middle between the 12th rib and the iliac crest, and hip circumference (HC) at the level of the anterior superior iliac spine at the broadest circumference below the waist using a measuring tape. The waist-to-hip ratio (WHR) was determined as WC (cm)/HC (cm). In accordance with the guidelines of the American Society of Hypertension \[[@B15]\], blood pressure was measured at approximately 08:00 with patients in a seated position using a mercury sphygmomanometer after a 5 min rest. It was recorded as the mean of three measurements taken at 1 min intervals.

A fasting blood sample was taken from the antecubital vein of each patient in the morning after polysomnographic monitoring. Fasting serum glucose and lipid profiles were measured in the hospital laboratory using routine procedures. Serum lipid profiles included total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), apolipoprotein A-I (apoA-I), apolipoprotein B (apoB), apolipoprotein E (apoE), and lipoprotein(a) (Lpa) (Hitachi, Tokyo, Japan). An immunoradiological method was used to measure the fasting serum insulin level. Insulin sensitivity was evaluated using the homeostasis model assessment of insulin resistance (HOMA-IR): HOMA-IR = fasting glucose (mmol/L) × fasting insulin(*μ*U/mL)/22.5 \[[@B16]\].

2.2. Polysomnography {#sec2.2}
--------------------

Overnight polysomnography (PSG) (Alice 4 or 5, Philips Respironics, Pittsburgh, PA) was performed from 22:00 to 06:00 according to the criteria of the American Academy of Sleep Medicine \[[@B17]\], including electroencephalogram (EEG), left and right electrooculogram (EOG), genioglossus electromyogram, electrocardiogram (ECG), pulse oxygen saturation, nose and mouth airflow, thoracic-abdominal movement, and body position. Apnea was defined as the complete cessation of airflow lasting for at least 10 s. Hypopnea was defined as a ≥50% reduction in airflow for at least 10 s with a decrease in oxyhemoglobin saturation of ≥3% or a ≥30% reduction in airflow for at least 10 s with a decrease in oxyhemoglobin saturation of ≥4%. The apnea hypopnea index (AHI) was defined as the number of apnea and hypopnea events per hour during sleep. The diagnosis of OSA was determined by AHI, and an AHI ≥5 events/h was defined as OSA \[[@B17]\].

2.3. Snoring Assessment {#sec2.3}
-----------------------

As snoring sounds are commonly described as a nuisance by the bed partner of the affected individual, information on snoring was collected from a bed partner or family member. Snoring intensity was evaluated using a 10 cm visual analogue scale (VAS) from 0 to 10: 0 represents no snoring, 1--3 represents minimally annoying, 4--6 represents moderately annoying, 7--9 represents annoying, and 10 represents extremely annoying \[[@B18]\]. We defined 0 as no snoring, 1--3 as mild snoring, 4--6 as moderate snoring, and 7--9 as severe snoring. Besides, in order to ensure a more even distribution for analysis, we incorporated 10 into the severe snoring group.

2.4. Metabolic Score {#sec2.4}
--------------------

MetS was defined according to the NCEP ATP III criteria with the modified WC criteria for Asians \[[@B19]\] as the presence of at least three of the following five clinical features: (1) elevated WC: ≥90 cm in men and ≥80 cm in women; (2) elevated TG: ≥1.70 mmol/L; (3) reduced HDL \<1.03 mmol/L in men and \<1.30 mmol/L in women; (4) elevated blood pressure: SBP ≥130 mmHg or DBP ≥85 mmHg or on antihypertensive drug treatment in a patient with a history of hypertension; and (5) elevated fasting glucose ≥5.6 mmol/L or on drug treatment for elevated glucose. A metabolic score was established as the total number of positive diagnostic criteria of metabolic syndrome in each participant \[[@B14]\].

2.5. Statistical Analysis {#sec2.5}
-------------------------

All statistical analyses were performed using SPSS (version 23.0; SPSS Inc., Chicago, IL). All values were examined for normal distribution prior to statistical analysis. Data are presented as the median (interquartile range \[IQR\]), mean ± standard deviation (SD), or *n* (%) if they are skewed, normally distributed, or categorical. Normally distributed or skewed variables were analyzed using the independent samples *t*-test or Mann--Whitney *U* test, respectively. Categorical variables were analyzed using the chi-square test or Fisher\'s exact test. The polynomial linear trend test was used to assess the linear trends across snoring intensity for metabolic score. Independent associations between snoring and MetS and its components were analyzed, using multivariable logistic regression after adjusting for relevant covariates. Odds ratios (ORs) are presented with 95% confidence intervals (CIs). In all analyses, *P* \< 0.05 was taken to indicate statistical significance.

3. Results {#sec3}
==========

3.1. Basic Characteristics {#sec3.1}
--------------------------

The 866 participants were divided according to snoring intensity into the simple snoring group (*n* = 679) and nonsnoring group (*n* = 187). The proportion of males was greater in the simple snoring group than in the nonsnoring group (63.0% vs. 41.7%, respectively, *P* \< 0.001). Compared to the nonsnoring group, simple snorers were more obese (evidenced by higher BMI, NC, WC, HC, and WHR, *P* \< 0.001), had higher fasting glucose levels, insulin levels, and HOMA-IR levels (*P* \< 0.001), and showed more severe lipid abnormalities (i.e., hyper-TC, hyper-TG, hyper-LDL, hyper-apoB, and hypo-apoA-I, *P* \< 0.05). Furthermore, simple snorers had a higher prevalence of MetS (18.0% vs. 9.1%, respectively, *P* = 0.003), and among simple snorers, the percent of participants scored from 0 to 5 was 24.9%, 33.6%, 23.6%, 12.7%, 4.1%, and 1.2%, respectively; among controls, the percent was 31%, 40.6%, 19.3%, 6.4%, 2.7%, and 0, respectively. Simple snorers were more likely to be current smokers and alcohol drinkers (*P* \< 0.001) ([Table 1](#tab1){ref-type="table"}).

Compared to female simple snorers, males snored louder (higher VAS score, *P* \< 0.001), were more obese (evidenced by higher BMI, NC, WC, HC, and WHR, *P* \< 0.05), had higher systolic and diastolic blood pressure (*P* \< 0.001), and had more severe dyslipidemia (i.e., higher TG, LDL, and apoB and lower HDL, apoA-I, and apoE, *P* \< 0.05). In addition, males were more likely to be current smokers and alcohol drinkers than females (*P* \< 0.001) ([Table 2](#tab2){ref-type="table"}).

3.2. Prevalence of MetS {#sec3.2}
-----------------------

The prevalence rates of MetS and its components in our study are shown in [Table 2](#tab2){ref-type="table"}. The prevalence rate of MetS was higher in simple snorers (18.0% vs. 9.1%, respectively, *P* = 0.003). Among its components, the prevalence rates of hypertension (29.3% vs. 18.7%, respectively, *P* = 0.004) and hyper-TG (25.9% vs. 12.8%, respectively, *P* \< 0.001) were significantly higher in simple snorers than in nonsnorers.

Subgroup analysis showed that there were differences between simple snorers and the nonsnoring group in both male and female participants. Among male participants, simple snorers only had a higher prevalence rate of hypertension compared with nonsnorers (33.2% vs. 14.1%, *P* = 0.001). Among female participants, simple snorers had a higher prevalence rate of MetS (19.1% vs. 9.2%, *P* = 0.018) and higher prevalence rates of abdominal obesity (30.7% vs. 22.0%, *P* = 0.005) and hyper-TG (16.3% vs. 6.4%, *P* = 0.011) compared with nonsnorers ([Table 3](#tab3){ref-type="table"}).

3.3. Association between Snoring and MetS {#sec3.3}
-----------------------------------------

A significant linear trend was observed between snoring intensity and metabolic score (*P* for trend = 0.008) ([Figure 2](#fig2){ref-type="fig"}). Simple snoring was associated with MetS, even after adjusting for age, sex, smoking status, and alcohol consumption (OR = 2.328, 95% CI: 1.340--4.045). Gender stratification analysis showed that such association was only significant among female participants (OR = 2.382, 95% CI: 1.136--4.994) ([Table 4](#tab4){ref-type="table"}).

Focusing on separate MetS components ([Table 5](#tab5){ref-type="table"}), simple snoring was significantly associated with hypertension (OR = 1.730, 95% CI: 1.130--2.650) among all participants after adjusting for confounding factors, such as age, gender, smoking status, alcohol consumption, and other MetS components. However, the results of gender stratification analysis showed that this relationship was only obvious in men (OR = 3.493, 95% CI: 1.748--6.979).

Simple snoring was significantly associated with abdominal obesity (OR = 1.810, 95% CI: 1.063--3.083) after adjusting for confounding factors, and this relationship was only significant in women (OR = 2.306, 95% CI: 1.245--4.270). Simple snoring was also significantly associated with hyper-TG (OR = 1.814, 95% CI: 1.097--2.998), and gender stratification analysis showed that this relationship was only significant in women (OR = 2.803, 95% CI: 1.146--6.856) after multivariable adjustment.

The associations between simple snoring and hypo-HDL/hyperglycemia were not significant.

No significant interaction between sex and snoring on MetS was observed through joint classification analysis (*P* for interaction = 0.836) ([Figure 3](#fig3){ref-type="fig"}).

4. Discussion {#sec4}
=============

The present study indicated that simple snoring was associated with higher prevalence of MetS, and there was a positive linear trend for metabolic score across snoring severity after adjusting for multiple variables. Furthermore, we found that simple snoring was independently associated with MetS and that female snorers were more vulnerable to metabolic disorders. No interaction was observed between sex and simple snoring on MetS.

Previous studies have demonstrated a relationship between snoring and MetS, but did not exclude the impact of repeated apnea and hypoxia \[[@B10], [@B11], [@B20]\]. A similar relationship was still found after excluding OSA patients from the whole sample. Furthermore, some studies showed that associations between snoring and MetS/MetS components only existed among females \[[@B7], [@B13], [@B21]--[@B24]\]. In the present study, although men showed more typical symptoms, such as snoring, than women, the metabolic effects of snoring were even greater in women. Furthermore, simple snoring was significantly associated with MetS in female snorers but not in male snorers. After controlling for confounding factors, the association with abdominal obesity/hyper-TG was more obvious among women. However, no significant interaction was observed between sex and snoring in our study. The mechanism involved in this gender difference may be as follows. Firstly, approximately 7% of premenopausal women have polycystic ovary syndrome, show hyperandrogenism, and have increased vulnerability to sleep disorders and metabolic disorders \[[@B7], [@B21]\]. Secondly, the levels of sex hormone secretion are reduced in postmenopausal women, with the most pronounced changes seen in estrogen reduction. The hormone levels change from estrogen predominance to androgen predominance, followed by increased incidence of snoring and metabolic disorders. Thirdly, compared with men, women tend to accumulate less visceral fat, but there are fewer *α*-adrenergic receptors in visceral adipose tissue in men indicating higher rates of lipolysis \[[@B25]\]. Finally, there existed gene-by-sex interaction on hepatic steatosis and females could accumulate more hepatic TG than males genetically \[[@B26]\].

Obesity is considered a predisposing factor for severe snoring, whereas snoring may further promote the development of obesity \[[@B27]\]. Abdominal obesity is not only a component of MetS, but a promoting factor of other components of MetS, such as IR, resulting in more serious metabolic problems \[[@B28]\]. Thus, the relationships among snoring, obesity, and MetS are complex. Elmasry et al. \[[@B29]\] suggested that snoring and obesity lead to increased odds for diabetes, with obesity playing the leading role, whereas snoring further increases the odds for developing diabetes on the basis of obesity. Other studies \[[@B11], [@B29]--[@B31]\] have shown that snoring increases the odds for metabolic disturbances, but the effect of snoring may be significantly attenuated or even eliminated after adjusting for obesity-related indicators, such as BMI or WHR. Thus, obesity may play a leading role in the interaction between snoring and metabolic disorders by activating chronic inflammatory reactions, as well as adipokine disorders \[[@B11]\]. In this study, simple snorers were more obese, and simple snoring was significantly associated with abdominal obesity after adjustment, including for other MetS components.

The relationship between snoring and hypertension remains unclear. Lindberg et al. reported that snoring was an independent risk factor for hypertension in men younger than 50 years old, whereas snoring did not significantly affect hypertension in older adults \[[@B32]\]. Hu et al. reported that snorers had significantly higher systolic and diastolic blood pressure levels, and snoring was significantly associated with hypertension in women \[[@B23]\]. Bixler et al. reported that in both men and women, snoring was independently correlated with hypertension, which was more obvious in young and normal-weight participants \[[@B33]\]. Two related studies in the Korean population indicated that snoring significantly increased the prevalence of hypertension independent of obesity \[[@B20]\]. In contrast, Nieto et al. reported that AHI was significantly associated with hypertension, whereas the relationship between habitual snoring and hypertension was not obvious \[[@B34]\]. In the present study, simple snorers showed significantly higher prevalence rates of hypertension than nonsnorers, and simple snoring was an independent risk factor for hypertension, which was more obvious in men than in women. The main underlying mechanism may lie in estrogen, which could influence artery stiffness, inhibit vascular remodel, and modulate the renin-angiotensin aldosterone system \[[@B35]\].

Previous studies have also drawn inconsistent conclusions regarding the relationship between snoring and IR. Some researchers reported that snoring was associated with diabetes and insulin sensitivity \[[@B29], [@B36]\], whereas other studies showed that although snoring was more common in men, it significantly increased the odds for diabetes or impaired glucose tolerance only in women \[[@B13], [@B21], [@B24]\]. A recent meta-analysis concluded that there was a strong association between snoring and diabetes in women, but not in men \[[@B7]\]. The association between simple snoring and hyperglycemia was not significant in our study, but simple snorers showed higher fasting glucose and insulin levels as well as a tendency for higher IR than nonsnorers.

There have been few previous studies on the relationship between snoring and dyslipidemia. Shin et al. reported that as snoring frequency increased, TG levels increased and HDL levels decreased and that snoring was associated with hyper-TG and hypo-HDL, but the effect of snoring was significantly attenuated after adjusting for other confounding factors. Cho et al. reported that snorers had higher prevalence rates of hyper-TG and hypo-HDL, but snoring did not increase the odds for dyslipidemia after taking various confounding factors into consideration \[[@B20]\]. In our study, simple snorers had higher levels of TC, TG, LDL, and apoB, lower apoA-I levels, and higher prevalence of hyper-TG than nonsnorers. Furthermore, the components of dyslipidemia may differ between genders, e.g., males showed higher TG, LDL, and apoB and lower HDL, apoA-I, and apoE than females. However, after multivariable adjustment, simple snoring was significantly associated with increased odds for hyper-TG only among females.

The mechanisms underlying the relationship between simple snoring and MetS have not been clarified. Through direct mechanical injury to the endothelium and local initiation of proinflammatory response, snoring vibration transmission may accelerate the development of carotid atherosclerotic plaque and contribute to MetS \[[@B37]--[@B40]\]. The physiological disturbances caused by snoring increase the number of microarousals during sleep \[[@B22]\], which could disrupt the restorative value of sleep, increase the activity of the sympathetic nervous system, and have a harmful impact on the hypothalamic-pituitary-adrenal axis with consequent elevations in serum cortisol, ultimately contributing to metabolic dysfunction \[[@B13], [@B41]--[@B45]\].

To our knowledge, this is the first study to investigate the associations between MetS/MetS components and simple snoring excluding the impact of OSA. Our study showed that snoring without repeated apnea and hypoxia was significantly associated with increased odds for MetS, which requires more attention regarding hypertension among male snorers and abdominal obesity and hyper-TG among female snorers. Our study also had some limitations. First, although self-reported snoring and snoring reported by roommates were found to be reliable measures in epidemiological studies, as validated by all-night sleep recording \[[@B46], [@B47]\], these are subjective measures to evaluate snoring. Second, as the duration of snoring was not collected, its impact on MetS could not be assessed.

In conclusion, the present study investigated the relationships between simple snoring and MetS/MetS components and concluded that, after eliminating the effects of repeated apnea and hypoxia, simple snoring was still independently associated with increased odds for MetS, especially in women. Furthermore, it suggested that clinicians should implement interventions, such as suggesting low-fat diet, low-sugar diet, and increased exercise for simple snorers to prevent MetS.
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###### 

Basic characteristics of nonsnorer participants and simple snorers.

                              Nonsnorers (*n* = 187)   Simple snorers (*n* = 679)   *P* value
  --------------------------- ------------------------ ---------------------------- -----------
  Age (years)                 42.00 (33.00, 49.00)     36.00 (30.00, 46.00)         0.002
  Male (%)                    78 (41.7%)               428 (63.0%)                  \<0.001
  BMI (kg/m^2^)               23.04 ± 3.11             24.15 ± 3.59                 \<0.001
  NC (cm)                     34.67 ± 3.29             36.80 ± 3.55                 \<0.001
  WC (cm)                     83.09 ± 10.09            86.99 ± 10.41                \<0.001
  HC (cm)                     94.37 ± 7.07             97.10 ± 7.07                 \<0.001
  WHR (cm)                    0.88 ± 0.07              0.90 ± 0.07                  0.011
  SBP (mmHg)                  119.19 ± 10.71           119.83 ± 14.39               0.573
  DBP (mmHg)                  76.55 ± 8.18             76.24 ± 9.72                 0.687
  FPG (mmol/L)                4.99 (4.62, 5.29)        5.05 (4.73, 5.37)            0.036
  FINS (*μ*U/mL)              5.52 (4.08, 8.48)        7.85 (5.65, 11.30)           \<0.001
  HOMA-IR                     1.20 (0.88, 1.90)        1.77 (1.23, 2.57)            \<0.001
  TC (mmol/L)                 4.22 (3.49, 4.82)        4.37 (3.80, 4.96)            0.001
  TG (mmol/L)                 0.90 (0.63, 1.32)        1.18 (0.78, 1.72)            \<0.001
  HDL (mmol/L)                1.14 (0.96, 1.34)        1.09 (0.96, 1.29)            0.237
  LDL (mmol/L)                2.39 (1.81, 2.93)        2.39 (1.81, 2.93)            \<0.001
  apoA-I (g/L)                1.14 (0.98, 1.29)        1.09 (0.96, 1.23)            0.023
  apoB (g/L)                  0.68 (0.57, 0.78)        0.76 (0.65, 0.88)            \<0.001
  apoE (mg/dL)                3.92 (3.24, 4.71)        3.90 (3.20, 4.79)            0.748
  Lpa (mg/dL)                 6.40 (3.75, 14.75)       8.10 (4.40, 16.80)           0.051
  MetS, *n* (%)               17 (9.1)                 122 (18)                     0.003
  Smokers, *n* (%)            15 (8.0)                 149 (21.9)                   \<0.001
  Alcohol drinkers, *n* (%)   16 (8.6)                 198 (29.2)                   \<0.001

BMI: body mass index; NC: neck circumference; WC: waist circumference; HC: hip circumference; WHR: waist-to-hip ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; apoA-I: apolipoprotein A-I; apoB: apolipoprotein B; apoE: apolipoprotein E; Lpa: lipoprotein(a); MetS: metabolic syndrome.

###### 

Basic characteristics of participants according to gender.

                              Nonsnorers           Simple snorers                                                   
  --------------------------- -------------------- -------------------- --------- ---------------- ---------------- ---------
  Age (years)                 38.31 ± 12.64        42.16 ± 10.43        0.029     36.84 ± 11.42    40.60 ± 12.39    \<0.001
  BMI (kg/m^2^)               23.14 ± 3.08         22.96 ± 3.15         0.074     24.44 ± 3.22     23.66 ± 4.11     0.010
  NC (cm)                     37.14 ± 2.98         32.89 ± 2.18         \<0.001   38.42 ± 2.73     34.04 ± 3.07     \<0.001
  WC (cm)                     86.08 ± 11.37        80.95 ± 8.49         0.001     89.22 ± 9.27     83.18 ± 11.15    \<0.001
  HC (cm)                     95.25 ± 7.25         93.74 ± 6.90         0.154     97.80 ± 6.68     95.89 ± 7.55     0.001
  WHR (cm)                    0.90 ± 0.08          0.86 ± 0.06          0.001     0.91 ± 0.06      0.87 ± 0.07      \<0.001
  SBP (mmHg)                  118.15 ± 8.27        119.93 ± 12.14       0.237     121.78 ± 13.74   116.50 ± 14.89   \<0.001
  DBP (mmHg)                  76.19 ± 8.23         76.81 ± 8.17         0.614     77.38 ± 9.57     74.28 ± 9.69     \<0.001
  FPG (mmol/L)                5.06 (4.55, 5.30)    4.97 (4.66, 5.26)    0.969     5.23 ± 0.88      5.12 ± 0.85      0.094
  FINS (*μ*U/mL)              5.07 (3.42, 7.74)    5.87 (4.47, 8.59)    0.085     9.25 ± 5.75      10.28 ± 16.57    0.341
  HOMA-IR                     1.13 (0.76, 1.63)    1.29 (0.94, 2.03)    0.173     2.24 ± 1.89      2.43 ± 4.30      0.517
  TC (mmol/L)                 4.08 (3.39, 4.71)    4.25 (3.63, 4.85)    0.266     4.45 ± 0.84      4.40 ± 0.96      0.450
  TG (mmol/L)                 0.94 (0.67, 1.56)    0.87 (0.62, 1.19)    0.013     1.57 ± 1.26      1.23 ± 0.94      \<0.001
  HDL (mmol/L)                1.05 (0.88, 1.21)    1.21 (1.03, 1.41)    \<0.001   1.08 ± 0.26      1.24 ± 0.28      \<0.001
  LDL (mmol/L)                2.41 (1.77, 2.99)    2.37 (1.90, 2.86)    0.934     2.79 ± 0.73      2.64 ± 0.83      0.016
  apoA-I (g/L)                1.06 (0.92, 1.20)    1.22 (1.03, 1.34)    \<0.001   1.07 ± 0.19      1.19 ± 0.23      \<0.001
  apoB (g/L)                  0.68 (0.56, 0.78)    0.67 (0.58, 0.78)    0.833     0.78 ± 0.16      0.73 ± 0.18      \<0.001
  apoE (mg/dL)                3.62 (3.02, 4.25)    4.07 (3.45, 4.75)    0.160     4.04 ± 1.33      4.32 ± 1.40      0.013
  Lpa (mg/dL)                 6.10 (3.85, 11.55)   7.40 (3.70, 18.10)   0.051     13.76 ± 15.54    14.54 ± 18.06    0.578
  MetS, *n* (%)               7 (9%)               10 (9.2%)            0.963     74 (17.3%)       48 (19.1%)       0.548
  Smoking, *n* (%)            15 (19.2%)           0                    \<0.001   143 (33.4%)      6 (2.4%)         \<0.001
  Alcohol drinkers, *n* (%)   15 (19.2%)           1 (0.9%)             \<0.001   177 (41.4%)      21 (8.4%)        \<0.001

BMI: body mass index; NC: neck circumference; WC: waist circumference; HC: hip circumference; WHR: waist-to-hip ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; apoA-I: apolipoprotein A-I; apoB: apolipoprotein B; apoE: apolipoprotein E; Lpa: lipoprotein(a); MetS: metabolic syndrome.

###### 

Prevalence of MetS in nonsnorers and simple snorers.

                                    Nonsnorers    Simple snorers   *P* value
  ------------------- ------------- ------------- ---------------- -----------
  Total               MetS          17 (9.1%)     122 (18.0%)      0.003
  Hypertension        35 (18.7%)    199 (29.3%)   0.004            
  Abdominal obesity   23 (12.3%)    113 (16.6%)   0.148            
  Hyper-TG            24 (12.8%)    176 (25.9%)   \<0.001          
  Hypo-HDL            101 (54.0%)   362 (53.3%)   0.866            
  Hyperglycemia       21 (11.2%)    108 (15.9%)   0.112            
                                                                   
  Males               MetS          7 (9.0%)      74 (17.3%)       0.065
  Hypertension        11 (14.1%)    142 (33.2%)   0.001            
  Abdominal obesity   5 (6.4%)      36 (8.4%)     0.551            
  Hyper-TG            17 (21.8%)    135 (31.5%)   0.084            
  Hypo-HDL            37 (47.4%)    207 (48.4%)   0.880            
  Hyperglycemia       8 (10.3%)     72 (16.8%)    0.144            
                                                                   
  Females             MetS          10 (9.2%)     48 (19.1%)       0.018
  Hypertension        15 (19.0%)    57 (22.7%)    0.885            
  Abdominal obesity   24 (22.0%)    77 (30.7%)    0.005            
  Hyper-TG            7 (6.4%)      41 (16.3%)    0.011            
  Hypo-HDL            64 (58.7%)    155 (61.8%)   0.587            
  Hyperglycemia       13 (11.9%)    36 (14.3%)    0.539            

MetS: metabolic syndrome; TG: triglyceride; HDL: high-density lipoprotein cholesterol.

###### 

Odds ratios for MetS.

                              Total   Males            Females                            
  --------------------------- ------- ---------------- --------- ---------------- ------- ----------------
  Unadjusted                  2.190   (1.282--3.742)   2.120     (0.938--4.794)   2.341   (1.137--4.821)
  Multivariable adjusted^∗^   2.328   (1.340--4.045)   1.615     (0.931--4.936)   2.382   (1.136--4.994)

^∗^Adjusted for age, sex, smoking status, and alcohol consumption.

###### 

Odds ratios for MetS components.

                              Total        Males            Females                                                             
  --------------------------- ------------ ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  Hypertension                Unadjusted   1.800            (1.203, 2.694)   3.024            (1.550, 5.902)   1.041            (0.606, 1.787)
  Multivariable adjusted^∗^   1.730        (1.130, 2.650)   3.493            (1.748, 6.979)   0.899            (0.501, 1.613)   
                                                                                                                                
  Abdominal obesity           Unadjusted   1.424            (0.880, 2.303)   1.341            (0.509, 3.531)   2.237            (1.262, 3.965)
  Multivariable adjusted^∗^   1.810        (1.063, 3.083)   0.943            (0.335, 2.653)   2.306            (1.245, 4.270)   
                                                                                                                                
  Hyper-TG                    Unadjusted   2.376            (1.498, 3.771)   1.653            (0.930, 2.938)   2.845            (1.233, 6.562)
  Multivariable adjusted^∗^   1.814        (1.097, 2.998)   1.443            (0.774, 2.690)   2.803            (1.146, 6.856)   
                                                                                                                                
  Hypo-HDL                    Unadjusted   0.972            (0.703, 1.345)   1.038            (0.640, 1.683)   1.135            (0.718, 1.796)
  Multivariable adjusted^∗^   0.876        (0.615, 1.249)   0.808            (0.477, 1.368)   0.897            (0.551, 1.460)   
                                                                                                                                
  Hyperglycemia               Unadjusted   1.495            (0.908, 2.461)   1.770            (0.816, 3.838)   1.236            (0.627, 2.437)
  Multivariable adjusted^∗^   1.217        (0.709, 2.092)   1.696            (0.736, 3.911)   0.899            (0.425, 1.899)   

^∗^Adjusted for age, sex, smoking status, alcohol consumption, and other MetS components. TG: triglyceride; HDL: high-density lipoprotein cholesterol.

[^1]: Guest Editor: Thirumagal Kanagasabai
